KONICA MINOLTA

About Konica Minolta

Giving Shape to Ideas

Konica Minolta Gives Presentation on Fluorescent Nanoimaging at a Life Science Symposium at Stanford University
– Participating in Drugs and Medical Devices Roundtable the Day Before –

Tokyo (December 26, 2016) – Konica Minolta, Inc. (Konica Minolta) gave a presentation on fluorescent nanoimaging, a technology used for drug discovery, at a symposium on innovative regenerative and cellular medicine and nanomedicine held at Stanford University in the U.S. on November 17, 2016.

■ Outline of the presentation ■

Title Industry Research in Nanomedicine
”High-Sensitivity Tissue Testing (HSTT) Technology”
Speaker Kiyotaka Fujii
Executive Officer and President, Global Healthcare
Konica Minolta, Inc.

■ Outline of the symposium ■

Title Stanford-Kanagawa Joint Symposium
Regenerative Medicine, Nanomedicine & Precision Medicine
Date November 17, 2016
Venue Munzer Auditorium at Beckman Center and Li Ka Shing Center, Stanford University
Organizers Stanford University and Kanagawa Prefecture

This symposium was organized jointly by Stanford University School of Medicine – the leader in life science research on the west coast of the U.S., which is the world’s hub in this field – and Kanagawa Prefecture, which is promoting its unique “Healthcare New Frontier” policy with a view to extending healthy life expectancy and creating a new market and industry. The symposium was attended by approximately 100 people, including Dr. Irving Weissman, a leading authority on iPS research, Dr. Lloyd Minor, Dean of Stanford University School of Medicine and other related personnel, clinical research department members from Harvard University and the U.S. Navy, as well as people from the Japanese and American healthcare companies.

Konica Minolta gave a presentation on High Sensitive Tissue Testing (HSTT), a new technology to accurately detect the proteins that manifest in cancer cells using fluorescent nanoparticles. This innovative technology greatly attracted the audience’s interest and the presentation was followed by a lively exchange of views on applications of this technology and other related issues.


Prior to the symposium, a roundtable titled “Advances in Healthcare and the Science of Drug and Device Development” was held on November 16, 2016, where representatives of administrative bodies including the FDA*1, PMDA*2, WHO, AMED*3 and other Japanese and American researchers engaged in discussions on the difficulties they are currently experiencing in obtaining approval from the FDA and the PMDA, and actions that need to be taken in the future. Konica Minolta stated that a difficulty is attributable to the difference in application procedures for approval between Japan and the U.S.; that the systems valid either in Japan or the U.S. only (such as the de novo process*4 of the U.S.) also contribute to current difficulties; and that sharing data between Japan and U.S. would enhance the efficiency of clinical trials and the application and approval processes.

On November 15, 2016, Konica Minolta signed a Memorandum of Understanding (MOU) with Stanford University to facilitate research cooperation. The MOU is expected to contribute to reinforcing the partnership between the two parties.

*1:
FDA stands for the Food and Drug Administration, a U.S. agency responsible for reviewing and approving drugs and medical devices to be launched in the U.S. market.
*2:
PMDA stands for the Pharmaceuticals and Medical Devices Agency, a Japanese agency responsible for three roles: reviewing and approving drugs and medical devices to be launched in the Japanese market; providing relief for health damage; and taking safety measures.
*3:
The Japan Agency for Medical Research and Development (AMED) is an agency that consistently engages in medical R&D from basic research to clinical applications, focusing especially on nine cooperative areas, such as regenerative medicine and cancer.
*4:
The FDA’s de novo process is designed to allow for simplified procedures for approval of novel devices without substantial risk. (Such a process is not permitted under the Pharmaceutical Affairs Law of Japan.)

Back to top